Were Amir Cohen’s Strata Critical Medical (SRTA) share sales under a Rule 10b5-1 plan?

Yes, at least one transaction was made under a Rule 10b5-1 trading plan. The footnote states the sale was executed pursuant to a Rule 10b5-1 plan adopted by Cohen on December 10, 2025, indicating the trade was pre-scheduled.

What prices did Amir Cohen receive for his Strata Critical Medical (SRTA) share sales?

Cohen’s reported weighted average sale prices were $5.79 and $5.91 per share. A footnote adds that certain shares on May 22, 2026 were sold in multiple trades between $5.81 and $6.02 per share, inclusive.

Strata Critical CAO sells 50,875 shares in May 2026

Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported open-market sales of company Class A common stock.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported open-market sales of company Class A common stock. On May 22, 2026, he sold 40,575 shares at a weighted average price of $5.91 per share. On May 21, 2026, he sold an additional 10,300 shares at a weighted average price of $5.79 per share. After these transactions, Cohen directly held 151,263 shares of Class A common stock. The filing notes that at least one of the transactions was executed under a pre-arranged Rule 10b5-1 trading plan, indicating the sales were scheduled in advance.

Insider Trade Summary 10b5-1

Net Seller: 50,875 shares

Net Sell 2 txns

Insider Cohen Amir

Role Chief Accounting Officer

Sold 50,875 shs ($299K)

Type	Security	Shares	Price	Value
Sale	Class A common stock, $0.0001 par value per share	40,575	$5.91	$240K
Sale	Class A common stock, $0.0001 par value per share	10,300	$5.79	$60K

Holdings After Transaction: Class A common stock, $0.0001 par value per share — 151,263 shares (Direct)

Footnotes (2)

F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2025.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.81 to $6.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Key Figures

Shares sold May 22, 2026: 40,575 shares Price May 22 sale: $5.91/share Shares sold May 21, 2026: 10,300 shares +4 more

7 metrics

Shares sold May 22, 2026 40,575 shares Open-market sale at $5.91 per share

Price May 22 sale $5.91/share Weighted average sale price for 40,575 shares

Shares sold May 21, 2026 10,300 shares Open-market sale at $5.79 per share

Price May 21 sale $5.79/share Weighted average sale price for 10,300 shares

Total shares sold 50,875 shares Net shares sold across two transactions

Shares held after sales 151,263 shares Direct Class A common stock holding post-transaction

Price range footnote $5.81–$6.02/share Multiple trades underlying weighted average on May 22, 2026

Key Terms

Rule 10b5-1 trading plan, open-market sale, weighted average price

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

What insider transactions did Strata Critical Medical (SRTA) report for Amir Cohen?

Amir Cohen sold Strata Critical Medical shares in two open-market transactions. He sold 10,300 shares at $5.79 on May 21, 2026, and 40,575 shares at $5.91 on May 22, 2026, as reported in the Form 4 filing.

How many Strata Critical Medical (SRTA) shares did Amir Cohen sell in total?

Amir Cohen sold a total of 50,875 Strata Critical Medical shares. The Form 4 shows 10,300 shares sold at $5.79 per share and 40,575 shares sold at $5.91 per share in two consecutive open-market transactions.

What is Amir Cohen’s remaining Strata Critical Medical (SRTA) shareholding after these sales?

After the reported sales, Amir Cohen directly holds 151,263 SRTA shares. This post-transaction holding reflects his remaining Class A common stock position as disclosed in the Form 4 following the May 2026 open-market sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/26/2026 - 04:49 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Amir

(Last)

(First)

(Middle)

C/O STRATA CRITICAL MEDICAL, INC.

666 THIRD AVENUE, 25TH FLOOR

(Street)

NEW YORK

10017

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A common stock, $0.0001 par value per share	05/21/2026		S⁽¹⁾		10,300	D	$5.79	191,838	D
Class A common stock, $0.0001 par value per share	05/22/2026		S⁽¹⁾		40,575	D	$5.91⁽²⁾	151,263	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.81 to $6.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Remarks:

	/s/ Melissa M. Tomkiel, Attorney-in-fact for Amir Cohen	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR